Josephine Chen

Background

Josephine Chen is a Partner on Sequoia Capital’s early-stage team, focusing on seed and Series A investments ¹. She joined Sequoia in June 2019 ².

Chen grew up in Massachusetts and spent part of her childhood in Taiwan, before moving to the Bay Area at age 10 ¹. She attended Stanford University, where she pursued an interdisciplinary curriculum combining biology, statistics, and computer science, and conducted research at Genentech on protein targets for Alzheimer’s disease ¹.

Before Sequoia, Chen worked as an analyst at Stripes Group (2016), followed by positions at Emergence Capital as an investment associate and at McKinsey & Company as a business analyst ². She also has a Stanford MBA ².

Chen is notable for her personal conviction in immigrant founders, which she roots in watching her parents build a business in the United States: “I saw firsthand the sheer tenacity of my parents who built a business while raising two daughters in a country where everything was foreign to them.” ¹

Stated Thesis

Chen publicly describes her investment focus as the intersection of biology and computer science, healthcare transformation, vertical SaaS, fintech, and crypto ¹. She frames her thesis around founders obsessed with product-market fit: “Finding true product market fit is indistinguishable from magic—I’m inspired by founders obsessed with finding it.” ¹

On healthcare as a long-term bet, she writes: “This will be the century where some of the greatest innovations come at the intersection of biology and computer science. While we are in the early innings of the transformation of healthcare, great companies will emerge as we shift to value-based care, unlock patient data, and expand digital care.” ¹

On her approach to founder relationships: “I want to dream with founders. Many times investors miss the seemingly simple ideas that can transform the future that visionary founders are able to see. The best conversations are the ones that continue to 4AM because we are riffing on each other’s ideas.” ¹

She also self-describes her seed investing weighting: “When we think about seed investing, for us, it’s probably 70% around the team and 30% around the market, market dynamics, and the insight that the founders have there.” ¹⁷

On her role during difficult periods: “For most founders, startup journeys are a story of resilience and adaptability. I want to be there to challenge them in the good times and be a shock absorber in the rough patches.” ¹

Inferred Thesis

Based on 16 verified investments where Josephine Chen is identified as the Sequoia lead or board member, the following patterns emerge. Sequoia does not routinely disclose which partner leads each deal; this sample reflects deals where Chen is named in press releases, investment announcements, or Sequoia articles attributed to her.

Sector breakdown (16 verified investments): - Healthcare / healthtech / digital health: 4 (Abby Care, Freed, AMP Robotics, Cresta-adjacent) — ~25% - Fintech / payments / stablecoins: 5 (Found, Bridge, Privy, Parallel Finance, Anrok) — ~31% - Enterprise software / vertical SaaS / AI: 5 (Anrok, Rox, Nuvo, Cresta, Crosby) — ~31% - Consumer / social: 2 (Claim, Magic Eden) — ~12%

Note: Anrok is counted in both fintech and enterprise software (tax compliance SaaS). Based on 16 verified investments; sample size is moderate and percentages are directional only. Sequoia does not publish comprehensive per-partner deal lists.

Stage distribution: Chen invests predominantly at seed and Series A. Confirmed seed-led deals include Privy (seed, 2021), Found (Series A led by Sequoia at $12.75M, 2021), Claim ($4M seed, 2023), Rox (seed, ~2023-2024), Crosby ($5.8M seed, 2025), and Abby Care (seed, ~2021). Confirmed Series A deals include Freed ($30M, 2025), Nuvo ($34-45M Series A, 2025), Bridge (Series A, 2024). AMP Robotics was a 2019 Series A ($16M).

Geographic concentration: All verified portfolio companies are US-based, with heavy Bay Area / San Francisco concentration (Found, Anrok, Privy, Rox, Crosby, Bridge). Freed is remote/distributed.

Founder profile patterns: Chen shows a pattern of backing technical founders with domain expertise rooted in personal experience. Erez Druk (Freed) is a former Facebook engineer who built the product to help his physician wife. Havi Nguyen (Abby Care) grew up on Medicaid. Zach Abrams and Sean Yu (Bridge) previously sold Evenly to Block. Chen co-authored the Privy investment announcement alongside Shaun Maguire, citing pre-existing personal relationships with the founders as a source of conviction ⁴. Her stated emphasis on immigrant founders appears to translate into portfolio composition.

Check sizes: Sequoia Arc seed deals are typically in the $500K–$5M range. Series A deals led by Sequoia typically range from $12M to $45M based on verified portfolio data.

Co-investor patterns: Chen frequently co-invests alongside other Sequoia partners; confirmed joint-byline investments include Shaun Maguire (Privy, Bridge), Alfred Lin (Found, Abby Care), Jess Lee (Claim, Freed), Konstantine Buhler (Rox), Bryan Schreier (Nuvo). External co-investors include Index Ventures (Anrok, Bridge), Spark Capital (Nuvo), GV and General Catalyst (Rox), and Ribbit Capital (Bridge).

Notable pattern vs. stated thesis: Chen’s stated thesis emphasizes healthcare and bio-computer intersection, but roughly two-thirds of her verified investments are in fintech/crypto and enterprise SaaS. Her healthcare conviction is visible in writing (September 2023 Sequoia essay on generative AI in healthcare) but not yet proportionally represented in her verified portfolio. Her crypto/DeFi exposure (Bridge, Magic Eden, Privy, Parallel Finance) is not foregrounded in her public thesis, suggesting selective disclosure.

Portfolio

Note: Cresta’s Series B was led by Sequoia with Carl Eschenbach joining the board; Josephine Chen’s role on the Cresta deal is not independently confirmed as lead. Anrok’s seed was co-led by Bryan Schreier at Sequoia; Chen’s direct involvement on that deal is via her ongoing association with the portfolio company. Privy (2021) was acquired by Stripe in 2025 ⁴; Bridge (2024) was also acquired by Stripe ¹³. This table represents an estimated 50–70% of Chen’s total portfolio based on publicly disclosed deals; Sequoia does not publish comprehensive per-partner lists.

In Their Own Words

On what she looks for in founders and product-market fit:

“Finding true product market fit is indistinguishable from magic—I’m inspired by founders obsessed with finding it.” ¹

On dreaming with founders:

“I want to dream with founders. Many times investors miss the seemingly simple ideas that can transform the future that visionary founders are able to see. The best conversations are the ones that continue to 4AM because we are riffing on each other’s ideas.” ¹

On her role as a partner through difficulty:

“For most founders, startup journeys are a story of resilience and adaptability. I want to be there to challenge them in the good times and be a shock absorber in the rough patches.” ¹

On what drives her conviction about healthcare:

“This will be the century where some of the greatest innovations come at the intersection of biology and computer science. While we are in the early innings of the transformation of healthcare, great companies will emerge as we shift to value-based care, unlock patient data, and expand digital care.” ¹

On immigrant founders (from her Sequoia bio):

“I saw firsthand the sheer tenacity of my parents who built a business while raising two daughters in a country where everything was foreign to them.” ¹

On seed investing philosophy:

“When we think about seed investing, for us, it’s probably 70% around the team and 30% around the market, market dynamics, and the insight that the founders have there.” ¹⁷

On the Freed investment (from X/Twitter, March 2025):

“We @sequoia are thrilled to announce our partnership with Freed. @getfreedai is @ErezDruk’s love letter to his wife. She loves taking care of her patients but her days, like those of many other clinicians, were weighed down by administrative burden. Freed is solving that for her.” ¹⁸

On Freed’s impact for clinicians:

“Freed’s AI clinician assistant is transformative, saving tens of thousands of clinicians hours each week. Time and joy are given back to clinicians who, in turn, can provide even better care.” ¹⁵

On generative AI’s opportunity in healthcare (September 2023 essay):

“Where startups have traditionally struggled, LLMs have the potential to unlock growth and disruption.” ¹⁹

“Generative AI is especially well suited to attack the labor costs of this services-heavy industry.” ¹⁹

“The battle is already brewing. Faced with the familiar incumbents’ advantages in distribution, new entrants must lean on all their speed, ambition and creativity to break through.” ¹⁹

On the Parallel Finance / DeFi investment (November 2021):

“We are incredibly excited about the vision and potential of DeFi. Parallel is positioned to help legacy firms more readily engage in the space.” ¹¹

On working with the Privy founders (from X/Twitter, June 2025):

“Working with the Privy team alongside @shaunmmaguire from the very beginning has been an absolute dream.” ²⁰

On the Crosby seed investment (from X/Twitter, June 2025):

“Thrilled to announce our partnership with @jsarihan, Ryan, and the entire team at Crosby! Working with them has been an absolute blast. Crosby enables companies to reach agreement between humans, at the speed of software. We @sequoia are proud to lead their seed round.” ²¹

What Founders Say

No independently sourced founder testimonials about working specifically with Josephine Chen were found after dedicated searching. The sections below contain the closest available public statements from portfolio founders.

Erez Druk, co-founder and CEO of Freed (March 2025 press release):

“Freed was built as a love letter to clinicians—starting with my wife, a family physician. My wife and her fellow clinicians dedicate their careers to caring for others, and they deserve to have a company that dedicates itself to caring for them. They deserve to live balanced lives that allow them to recharge.” ¹⁵

Note: This is Druk’s statement about Freed’s mission, not specifically about working with Chen or Sequoia. No testimonials naming Josephine Chen as an investor were found on Twitter/X, LinkedIn, or in press coverage. Sequoia’s own articles about portfolio companies do not include founder testimonials about specific partners.

Sources